Jacqueline Kunzler net worth and biography

Jacqueline Kunzler Biography and Net Worth

Jacqueline (Jackie) Kunzler, Ph.D. is senior vice president, chief quality officer.

Kunzler joined Baxter in 1993 and has served in roles of increasing responsibility across Baxter’s research & development, international marketing, and quality organizations, most recently as senior vice president, chief quality officer.

She serves as executive sponsor of Baxter Equality Network, a business resource group for employees dedicated to supporting inclusion of lesbian, gay, bisexual and transgender professionals and their straight allies at Baxter. Kunzler also serves as a member of Baxter's Global Inclusion Council.

Kunzler obtained her bachelor’s degree in biology and medical technology (laboratory medicine) from the University of Iowa. She also received a master’s degree in toxicology from the University of Florida School of Veterinary Medicine, and MBA from Benedictine University with continuing education at Harvard Business School and a Ph.D. in neuroscience/cell biology from the University of Illinois College of Medicine. She is boarded by American Society of Clinical Pathologists. She also serves as a committee member with PDA/FDA (drugs) and MDIC/FDA (devices).

What is Jacqueline Kunzler's net worth?: The estimated net worth of Jacqueline Kunzler is at least $493,387.50 as of February 21st, 2023. Dr. Kunzler owns 16,725 shares of Baxter International stock worth more than $493,388 as of December 22nd. This net worth evaluation does not reflect any other investments that Dr. Kunzler may own. Learn More about Jacqueline Kunzler's net worth.
How do I contact Jacqueline Kunzler?: The corporate mailing address for Dr. Kunzler and other Baxter International executives is One Baxter Parkway DF2-1W, Deerfield IL, 60015. Baxter International can also be reached via phone at (224) 948-2000 and via email at [email protected]. Learn More on Jacqueline Kunzler's contact information.
Has Jacqueline Kunzler been buying or selling shares of Baxter International?: Jacqueline Kunzler has not been actively trading shares of Baxter International during the last quarter. Most recently, Jacqueline Kunzler sold 3,813 shares of the business's stock in a transaction on Tuesday, February 21st. The shares were sold at an average price of $40.50, for a transaction totalling $154,426.50. Following the completion of the sale, the senior vice president now directly owns 16,725 shares of the company's stock, valued at $677,362.50. Learn More on Jacqueline Kunzler's trading history.
Who are Baxter International's active insiders?: Baxter International's insider roster includes Giuseppe Accogli (SVP), John Forsyth (Director), Andrew Frye (SVP), James Gavin, III (Director), Jacqueline Kunzler (SVP), Sean Martin (SVP), Jeanne Mason (SVP), Brian Stevens (CAO), and Albert Stroucken (Director). Learn More on Baxter International's active insiders.

Jacqueline Kunzler Insider Trading History at Baxter International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/21/2023	Sell	3,813	$40.50	$154,426.50	16,725
9/5/2019	Sell	5,934	$88.12	$522,904.08	3,089
6/19/2019	Sell	593	$80.46	$47,712.78	9,023

Jacqueline Kunzler Buying and Selling Activity at Baxter International

Baxter International Company Overview

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Today's Range

Now: $29.50

$29.17

$29.99

50 Day Range

MA: $33.70

$28.90

$36.91

2 Week Range

Now: $29.50

$28.62

$44.01

Volume

12,194,859 shs

Average Volume

4,174,975 shs

Market Capitalization

$15.06 billion

P/E Ratio

147.51

Dividend Yield

2.35%

Beta

0.58

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.